Assembly Biosciences Announces Exercise Of Option To Share 40% Of U.S. Development Costs And Profits For Gilead-Partnered HSV Helicase-Primase Inhibitor Program In Recurrent Genital Herpes

Loading news article.

Assembly Biosciences Announces Exercise Of Option To Share 40% Of U.S. Development Costs And Profits For Gilead-Partnered HSV Helicase-Primase Inhibitor Program In Recurrent Genital Herpes | WAPE

Assembly Biosciences Announces Exercise Of Option To Share 40% Of U.S. Development Costs And Profits For Gilead-Partnered HSV Helicase-Primase Inhibitor Program In Recurrent Genital Herpes

Article summary

Related companies

Comments —